As a relatively mature field in the pharmaceutical market, API have been constantly changing in recent years based on external environment and policy situations.
Firstly, from a global perspective, the pharmaceutical market continues to expand, and the raw material pharmaceutical industry maintains stable growth and good development trends. Secondly, from the domestic situation, due to the increasing pressure of production costs and environmental protection costs in countries such as Europe and America, as well as the improvement of process technology, production quality, and drug market registration and certification capabilities of Chinese raw material drug production enterprises, the transfer of raw material drug enterprises to China has accelerated; In addition, with the continuous increase in the number of original research drug varieties with expired patents, as well as the rapid increase in the variety, quantity, and quality of domestic generic drugs, China's raw material drug market has ushered in huge market opportunities.
The field of API in China continues to heat up, with many capital and enterprises participating. The inherent pattern of API is gradually being broken. However, in the context of increasing environmental requirements, continuously improving drug quality, and continuously strengthening industry supervision, the transformation and upgrading of the industrial structure of API has become an inevitable trend, and the stable supply of API is also crucial for pharmaceutical companies. The increasing environmental pressure and regulatory efforts in China, the increasing number of monopolistic varieties, and the rising prices of API, have led to more and more domestic production and research and development enterprises preferring to use imported API for their own formulations.